Article Text
Abstract
Introduction Mucinous ovarian cancer presents unique challenges in management due to its distinct histopathological characteristics. The role of lymphadenectomy in early-stage disease remains controversial in clinical practice. The objective of this study was to evaluate the impact of lymphadenectomy on overall survival in early-stage mucinous ovarian cancer.
Methods A retrospective cohort study reviewed medical records from 2009 to 2016, identifying 121 patients diagnosed with stage I-II mucinous ovarian cancer. These patients were categorized based on whether they underwent surgery with or without lymphadenectomy. Both groups underwent standard surgical procedures and received adjuvant chemotherapy according to the institute’s protocol. Clinicopathological and survival outcomes were then compared.
Results Among the 121 patients studied, the median follow-up time was 87.8 months. Analysis revealed that there were no significant differences in the 5-year survival rates (5-year OS) and 5-year progression-free survival rates (5yr-PFS) between the groups (5-year OS: 97.3% vs. 91.3%, P = 0.13; 5-year PFS: 97.2% vs. 91.1%, P = 0.13). Furthermore, no independent factors were found to be associated with either 5-year OS or 5-year PFS in either group. Notably, lymphadenectomy resulted in adverse events including one case of lymphocyst and significantly prolonged operative times (mean operative time: 240.0 mins vs. 182.5 mins, P < 0.001).
Conclusion/Implications Lymphadenectomy for early-stage mucinous ovarian cancer not only failed to improve the 5-year overall survival and 5-year progression-free survival rates but also resulted in increased adverse events.